Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans. - Wikidata - awgldk - TriplyDB

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

http://www.wikidata.org/entity/Q34323499

about

The utility of apoptosis inhibitor of macrophages as a possible diagnostic marker in patients with Crohn's disease.Impact of feline AIM on the susceptibility of cats to renal disease.A proteolytic modification of AIM promotes its renal excretion.AIM/CD5L: a key protein in the control of immune homeostasis and inflammatory disease.Apoptosis inhibitor of macrophage (AIM) reduces cell number in canine histiocytic sarcoma cell lines.The haptoglobin beta subunit sequesters HMGB1 toxicity in sterile and infectious inflammation.Association of apoptosis inhibitor of macrophage (AIM) expression with urinary protein and kidney dysfunction.Apoptosis inhibitor of macrophage protein enhances intraluminal debris clearance and ameliorates acute kidney injury in mice.Tricking an ancient immune function to eradicate hepatocellular carcinoma.AIM associated with the IgM pentamer: attackers on stand-by at aircraft carrier.Dietary fructose-induced hepatocellular carcinoma development manifested in mice lacking apoptosis inhibitor of macrophage (AIM).A scavenging system against internal pathogens promoted by the circulating protein apoptosis inhibitor of macrophage (AIM)The IgM pentamer is an asymmetric pentagon with an open groove that binds the AIM protein Independent modes of disease repair by AIM protein distinguished in AIM-felinized mice

P2860

Q36305141-A8F9DC36-1CFB-4089-93C5-8D4ACC8A0324 Q37330375-581AD130-06DA-419D-8F84-08958B230EF9 Q37483757-07B60B1E-5E75-4256-A763-9620F706C7A0 Q38517909-8E77001E-5CCF-4928-A7AA-E9F3595F1C1D Q38767277-DE9B16F5-E42B-4055-B9CF-389911FF5BF2 Q40229508-D19ABE34-10E9-465F-993E-DF2374F956AF Q40804668-12D4D63C-8885-4FF1-9A34-9EF691C34DAF Q41003256-1C2EECCA-3974-4191-A239-7F2F84FFDB99 Q41999933-96BD774A-9233-4EB9-BC48-C274FEA9E498 Q49634180-ADD72D79-C8D0-4872-ADCF-97831410BD22 Q51344927-984A8636-4CFD-440C-B891-B099D5A88254 Q57477275-804D6EC1-1592-45E9-9F5F-99168E085974 Q57479101-D79149A9-F3A1-4918-ACAC-F2A9BAE22400 Q58769346-2DE49E3A-F2CE-4382-B23A-F535B2A21020

P2860

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

http://www.wikidata.org/entity/Q34323499

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

@ast

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

@en

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

@nl

type

label

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

@ast

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

@en

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

@nl

prefLabel

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

@ast

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

@en

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

@nl

P1433

Q34323499-8B57BDC4-A85E-494E-8AA1-CCE58B7131AE

P1476

Q34323499-F57F5017-8EB3-4E54-BCED-4FD3049E94B4

P2093

Q34323499-0F667DF5-C263-4D3B-A5B5-57CB09D35699

Q34323499-1C675CFE-D7D2-4210-8759-29C5D99B2D37

Q34323499-24FFAFF6-0DB0-464D-8A7D-92696608E036

Q34323499-2DA9F589-F840-40B5-B1FB-8DD111296577

Q34323499-37CC3851-2003-4040-B736-17D34A620E01

Q34323499-3F915868-E744-4498-B14F-B4739EA04B7C

Q34323499-456FB5B7-EDCF-4900-9ABC-B69F79AEDBD7

Q34323499-46E386AE-13C4-444B-A0D8-6583E0703C45

Q34323499-4DC462AB-2982-49AE-ACDD-4739EE46BE5C

Q34323499-56C7CF79-D4D1-4979-A0A2-C096CBE1E5D7

P2860

Q34323499-0229B5A3-D717-4ABA-9693-C0A42FDC8C2A

Q34323499-07626E49-E44C-4760-B431-0736851A9267

Q34323499-09035660-E389-423F-B471-95BB52984440

Q34323499-0A8AC8F6-12B7-4232-809B-F3F948412D81

Q34323499-199C42D1-966B-4825-8D7E-5974393DA400

Q34323499-2E9D8808-EE43-43E9-B296-6FD8A0DFE5BD

Q34323499-2EBBE460-291D-424D-9D30-C7C771672C01

Q34323499-33ECCA69-2D2C-4A4F-87BD-8148573F8589

Q34323499-351C03D1-D36B-4F1C-9A9B-FAFAD13CE114

Q34323499-52B2CD64-3B26-4F61-A50D-E62E0E9930AA

P304

Q34323499-9681850E-FC49-4232-A07A-E401DD6E18BF

P31

Q34323499-38525966-43BD-4A41-989C-0C6AE8E49578

P356

Q34323499-3004BABD-7FC4-48AD-9D63-AB52BF4B57EF

P407

Q34323499-5501D04A-B83A-4F84-BFD1-2D16929283B1

P433

Q34323499-D07FED3C-5B44-488A-931E-7D98BCB473D4

P478

Q34323499-5FFA5310-A492-4AC7-A4AE-B216B56A193B

P50

Q34323499-6523D75D-3EF6-4F8D-93B2-1002A436DFFE

Q34323499-9853BF77-249B-4E4B-8D4F-E0C21BA1EBB9

Q34323499-B2C476C1-0CA7-4330-8001-82381747DE93

P577

Q34323499-C9484240-4032-4918-8F98-0C0EE7863CF2

P5875

Q34323499-D810FD6C-B39B-469F-B2A9-80EB77217D0B

P698

Q34323499-1350B55C-1AC7-473B-B811-4732FC79AC60

P932

Q34323499-27077BA3-E88C-406C-9C87-B6A085F901A9

P356

JOURNAL.PONE.0109123

P1433

P1476

Circulating AIM as an indicator of liver damage and hepatocellular carcinoma in humans.

@en

P2093

Akemi Nishijima

http://www.w3.org/2001/XMLSchema#string

Jun Takahashi

http://www.w3.org/2001/XMLSchema#string

Kayo Aoyama

http://www.w3.org/2001/XMLSchema#string

Ken-ichi Yamamura

http://www.w3.org/2001/XMLSchema#string

Ken-ichiro Inoue

http://www.w3.org/2001/XMLSchema#string

Kiyohiro Izumino

http://www.w3.org/2001/XMLSchema#string

Maki Maeda

http://www.w3.org/2001/XMLSchema#string

Masanori Abe

http://www.w3.org/2001/XMLSchema#string

Mihoko Ban

http://www.w3.org/2001/XMLSchema#string

Satoko Arai

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

IgM are associated to Sp alpha (CD5 antigen-like)

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression

Nonalcoholic fatty liver disease

Stabilization and augmentation of circulating AIM in mice by synthesized IgM-Fc.

A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease

17beta-estradiol enhances the response of plasmacytoid dendritic cell to CpG

P304

e109123

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0109123

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Ryosuke Tateishi

P577

2014-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266744126

http://www.w3.org/2001/XMLSchema#string

P698

25302503

http://www.w3.org/2001/XMLSchema#string

P932

4193837

http://www.w3.org/2001/XMLSchema#string